We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial.
- Authors
de Botton, S.; Chevret, S.; Coiteux, V.; Dombret, H.; Sanz, M.; San Miguel, J.; Caillot, D.; Vekhoff, A.; Gardembas, M.; Stamatoulas, A.; Conde, E.; Guerci, A.; Gardin, C.; Fey, M.; Cony Makhoul, D.; Reman, O.; de la Serna, J.; Lefrere, F.; Chomienne, C.; Degos, L.
- Abstract
Treatment combining ATRA and chemotherapy (CT) has improved the outcome of APL patients, by comparison with CT alone. ATRA syndrome is a life-threatening complication of ATRA treatment whose prophylaxis remains somewhat controversial. In APL93 trial, newly diagnosed APL patients ≤65 years and with initial WBC counts below 5000/mm³ were randomized between ATRA until CR achievement followed by CT (ATRA → CT) and ATRA with early addition of CT, on day 3 of ATRA treatment (ATRA + CT). The incidence of ATRA syndrome in the ATRA → CT arm was 18% (22/122) as compared to 9.2% (17/184) in the ATRA + CT arm (P = 0.035). In the ATRA → CT arm, three (2.5%) patients died from ATRA syndrome, as compared to one (0.5%) in the ATRA + CT group. Early addition of chemotherapy to ATRA in newly diagnosed APL with low WBC counts significantly reduced the incidence of ATRA syndrome.
- Subjects
MYELOID leukemia; DRUG therapy
- Publication
Leukemia (08876924), 2003, Vol 17, Issue 2, p339
- ISSN
0887-6924
- Publication type
Article